|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 2985 Drew Street |
Address2 |
|
| City | Clearwater |
State | FL |
Zip Code | 33759 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Clearwater |
State | FL |
Zip Code | 33759 |
Country | USA |
|
5. Senate ID# 400855514-12
|
||||||||
|
6. House ID# 418910000
|
||||||||
| TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: John Learn |
Date | 1/22/2024 10:50:46 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Met with staff in Congresswoman Laurel Lees staff to discuss general healthcare issues in district. Specifically labor issues, regarding the cost of staffing, and the SAVE Act S. 2768.
Hosted CMS Deputy Administrator to discuss: 1) 340B eligibility challenges around the policy implemented in the FY 24 IPPS rule pertaining to the Medicare DSH calculation and using uncompensated care pool days under Floridas Low Income Pool Program. 2) expansion of the acute hospital-at-home waiver program to include observation patients.
Hosted Congresswoman Kathy Castor press conference to discuss relevant toy safety and online safety items for children during the holiday season, utilizing the U.S. Public Interest Research Group annual report, Trouble in Toyland.
Met virtually for an introductory conversation with Congressman Vern Buchanans health staff to discuss H@H program expansion and give overview of BayCare Health System operations.
Meetings with staff in: Congressman Bilirakis office to discuss 340B drug pricing program on the aforementioned FY 24 IPPS rule policy pertaining to Medicare DSH calculation, Senator Scotts office to discuss 340B program oversight generally and Healthcare legislative packages, H.R.5378 and S. 2840, introductory meeting to discuss who BayCare is and our scope with Cong. Scott Franklins staff, discussion against price transparency provisions in S. 2840 and H.R. 5378 with Senator Rubios staff and further discussion around the potential legislative expansion to the hospital-at-home waiver program with observation patients, meeting with Congresswoman Laurel Lees staff on the SAVE Act H.R. 5378.
Meeting with Congresswoman Kathy Castors staff to discuss outcomes within the BayCare@Home program and our vision for expansion of the current acute hospital-at-home waiver to include observation patients.
Introductory meeting with new regional Senator Rubio staffer to discuss who BayCare is and the work we do in the community.
Provided formal comment letter for the Laboratory Developed Test Rule - Docket No. FDA-2023-N-2177: Medical Devices: Laboratory Developed Tests Proposed Rule
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Learn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Pertaining to Docket No. FDA-2023-N-2177: Medical Devices: Laboratory Developed Tests Proposed Rule, we advocated for more flexibility and no additional regulatory burden that will inhibit sophisticated laboratories such as BayCare's from acting effectively in real time situations to mitigate emerging health concerns in the community.
Advocated against healthcare price transparency provisions within HR 5378 and S 2840 that would provide additionally burdensome reporting to further care sites that will hamper hospital negotiations with payors and require FTEs and excessive hours to satisfy.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Learn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Discussed current activity in Congress on 340B and the lack of accountability on drug manufacturers as well as the programming BayCare provides the community with the 340B savings. These programs include the Medication Assistance Program to ensure all in our community have access to the prescription drugs they require (we take referrals from anyone, not just BayCare patients/providers) and the Pharmacy Transition of Care team that helps improve medication adherence and transition/care coordination for those returning home with various prescriptions. Also discussed the concern with the removal of 1115 waiver days or uncompensated care pool days in the inclusion of the Medicaid DSH calculation for the purposes of 340B qualification.
17. House(s) of Congress and Federal agencies Check if None
Centers For Medicare and Medicaid Services (CMS), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Learn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |